151 related articles for article (PubMed ID: 32139504)
41. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
[TBL] [Abstract][Full Text] [Related]
42. Plasma Glucose Levels Affect Cerebral 18F-FDG Distribution in Cognitively Normal Subjects With Diabetes.
Ishibashi K; Onishi A; Fujiwara Y; Ishiwata K; Ishii K
Clin Nucl Med; 2016 Jun; 41(6):e274-80. PubMed ID: 26859211
[TBL] [Abstract][Full Text] [Related]
43. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
[TBL] [Abstract][Full Text] [Related]
44. Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease.
Ouchi Y; Yoshikawa E; Futatsubashi M; Yagi S; Ueki T; Nakamura K
J Nucl Med; 2009 Aug; 50(8):1260-6. PubMed ID: 19617327
[TBL] [Abstract][Full Text] [Related]
45. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
[TBL] [Abstract][Full Text] [Related]
46. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
[TBL] [Abstract][Full Text] [Related]
47. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
[TBL] [Abstract][Full Text] [Related]
48. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
[TBL] [Abstract][Full Text] [Related]
49. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease.
Venkataraman AV; Mansur A; Rizzo G; Bishop C; Lewis Y; Kocagoncu E; Lingford-Hughes A; Huiban M; Passchier J; Rowe JB; Tsukada H; Brooks DJ; Martarello L; Comley RA; Chen L; Schwarz AJ; Hargreaves R; Gunn RN; Rabiner EA; Matthews PM
Sci Transl Med; 2022 Aug; 14(658):eabk1051. PubMed ID: 35976998
[TBL] [Abstract][Full Text] [Related]
50. Two distinct pathological substrates associated with MMSE-pentagons item deficit in DLB and AD.
Beretta L; Caminiti SP; Santangelo R; Magnani G; Ferrari-Pellegrini F; Caffarra P; Perani D
Neuropsychologia; 2019 Oct; 133():107174. PubMed ID: 31446008
[TBL] [Abstract][Full Text] [Related]
51. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
52. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
[TBL] [Abstract][Full Text] [Related]
53. Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD.
Richter N; Nellessen N; Dronse J; Dillen K; Jacobs HIL; Langen KJ; Dietlein M; Kracht L; Neumaier B; Fink GR; Kukolja J; Onur OA
Neuroimage Clin; 2019; 24():101978. PubMed ID: 31422337
[TBL] [Abstract][Full Text] [Related]
54. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
Womack KB; Diaz-Arrastia R; Aizenstein HJ; Arnold SE; Barbas NR; Boeve BF; Clark CM; DeCarli CS; Jagust WJ; Leverenz JB; Peskind ER; Turner RS; Zamrini EY; Heidebrink JL; Burke JR; DeKosky ST; Farlow MR; Gabel MJ; Higdon R; Kawas CH; Koeppe RA; Lipton AM; Foster NL
Arch Neurol; 2011 Mar; 68(3):329-37. PubMed ID: 21059987
[TBL] [Abstract][Full Text] [Related]
55. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
[TBL] [Abstract][Full Text] [Related]
56. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
57. FDG PET imaging in patients with pathologically verified dementia.
Hoffman JM; Welsh-Bohmer KA; Hanson M; Crain B; Hulette C; Earl N; Coleman RE
J Nucl Med; 2000 Nov; 41(11):1920-8. PubMed ID: 11079505
[TBL] [Abstract][Full Text] [Related]
58. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
59. Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers.
Ishibashi K; Onishi A; Fujiwara Y; Ishiwata K; Ishii K
J Nucl Med; 2015 Feb; 56(2):229-33. PubMed ID: 25572094
[TBL] [Abstract][Full Text] [Related]
60. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
